MediWound to Participate in Upcoming March Investment Conferences
YAVNE,
Cowen 41st Annual |
|
Date: | |
Time: | |
Oppenheimer 31st Annual Healthcare Conference |
|
Date: | |
Time: |
A live webcast of each event will be available on the Events page of the Investors section of the Company's website: www.mediwound.com. A replay of each webcast will be available on the Company’s website for approximately 30 days.
About MediWound Ltd.
NexoBrid®, our first commercialized biological product for non-surgical and rapid eschar removal of deep, partial and full-thickness thermal burns without harming viable tissue, is currently marketed in the
EscharEx®, our next-generation bioactive topical therapeutic under development in the
MediWound’s third innovative product candidate, MWPC005, is a topical drug under development for the treatment of non-melanoma skin cancer.
Committed to innovation, we are dedicated to improving quality of care and patient lives. For more information, please visit www.mediwound.com.
Contacts: | |
Boaz Gur-Lavie | |
Chief Financial Officer | Managing Director, |
212-915-2568 | |
ir@mediwound.com | jeremy@lifesciadvisors.com |
Source: MediWound Ltd.